NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Forecast, Price & News $1.02 -0.05 (-4.67%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$0.96▼$1.0750-Day Range$0.86▼$2.4252-Week Range$0.22▼$2.42Volume217,500 shsAverage Volume271,886 shsMarket Capitalization$19.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Virios Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.42% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.10Based on 2 Articles This WeekInsider TradingAcquiring Shares$51,186 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.34) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector602nd out of 962 stocksPharmaceutical Preparations Industry274th out of 448 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Virios Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.42% of the outstanding shares of Virios Therapeutics have been sold short.Short Interest Ratio / Days to CoverVirios Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Virios Therapeutics has recently decreased by 17.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVirios Therapeutics does not currently pay a dividend.Dividend GrowthVirios Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIRI. Previous Next 3.4 News and Social Media Coverage News SentimentVirios Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Virios Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for VIRI on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows3 people have added Virios Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Virios Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,186.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.96% of the stock of Virios Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Virios Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Virios Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Virios Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVirios Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Virios Therapeutics (NASDAQ:VIRI) StockVirios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.Read More VIRI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRI Stock News HeadlinesSeptember 18, 2023 | finance.yahoo.comVirios Therapeutics Announces Termination of At-The-Market Sales AgreementSeptember 16, 2023 | americanbankingnews.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest UpdateSeptember 21, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 13, 2023 | americanbankingnews.comVirios Therapeutics (NASDAQ:VIRI) Shares Down 3.2% September 12, 2023 | finance.yahoo.comVirios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023August 15, 2023 | finance.yahoo.comVIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…August 14, 2023 | benzinga.comWhat In The World Is Going On With Virios Therapeutics (VIRI) Stock?August 14, 2023 | marketwatch.comVirios Therapeutics Shares Rise 11% After Halt to At-The-Market Offering SalesSeptember 21, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.August 14, 2023 | finance.yahoo.comVirios Therapeutics Announces Halt to At-The-Market Offering SalesAugust 12, 2023 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | finance.yahoo.comVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | benzinga.comVirios Therapeutics's Earnings OutlookAugust 9, 2023 | finance.yahoo.comVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaAugust 3, 2023 | finance.yahoo.comVirios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023August 2, 2023 | msn.comVirios Therapeutics (VIRI) Price Target Increased by 75.00% to 3.57July 24, 2023 | finance.yahoo.comVIRI: Encouraging Results for IMC-2 in Long COVID…July 17, 2023 | finance.yahoo.comVirios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M PeopleJuly 17, 2023 | finance.yahoo.comVirios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyJune 12, 2023 | seekingalpha.comCCL, S and LL are among pre market gainersMay 25, 2023 | finance.yahoo.comVirios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 16, 2023 | finance.yahoo.comVIRI: Ready to Move IMC-1 Into Phase 3 Program…May 15, 2023 | finance.yahoo.comVirios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat FibromyalgiaMay 12, 2023 | marketwatch.com10-Q: VIRIOS THERAPEUTICS, INC.May 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Virios Therapeutics (VIRI)May 11, 2023 | benzinga.comRecap: Virios Therapeutics Q1 EarningsMay 11, 2023 | finance.yahoo.comVirios Therapeutics Announces First Quarter 2023 Financial ResultsSee More Headlines Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VIRI Company Calendar Last Earnings8/10/2023Today9/20/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VIRI CUSIPN/A CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.40% Return on Assets-97.92% Debt Debt-to-Equity RatioN/A Current Ratio10.02 Quick Ratio10.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book1.16Miscellaneous Outstanding Shares19,247,000Free Float17,245,000Market Cap$19.63 million OptionableNot Optionable Beta1.95 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Gregory Duncan (Age 58)Chairman & CEO Comp: $559.59kDr. William L. Pridgen M.D. (Age 62)Founder & Director Comp: $35kMs. Angela Walsh (Age 56)CFO, SVP of Fin., Corp. Sec. & Treasurer Comp: $281.28kDr. R. Michael Gendreau M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $420.64kMr. Ralph D. Grosswald M.P.H. (Age 54)Sr. VP of Operations Ms. Carol Duffy Ph.D.Chief Scientific AdvisorMore ExecutivesKey CompetitorsMedicenna TherapeuticsNASDAQ:MDNACellectar BiosciencesNASDAQ:CLRBeFFECTOR TherapeuticsNASDAQ:EFTRKhosla Ventures AcquisitionNASDAQ:KVSAAcer TherapeuticsNASDAQ:ACERView All CompetitorsInsiders & InstitutionsWilliam PridgenBought 15,335 shares on 8/21/2023Total: $19,935.50 ($1.30/share)Gregory Scott DuncanBought 25,000 shares on 8/17/2023Total: $31,250.00 ($1.25/share)Citadel Advisors LLCBought 33,298 shares on 8/15/2023Ownership: 0.182%State Street CorpBought 42,200 shares on 8/14/2023Ownership: 0.289%Geode Capital Management LLCBought 86,983 shares on 8/11/2023Ownership: 0.805%View All Insider TransactionsView All Institutional Transactions VIRI Stock - Frequently Asked Questions How have VIRI shares performed in 2023? Virios Therapeutics' stock was trading at $0.2360 on January 1st, 2023. Since then, VIRI shares have increased by 332.2% and is now trading at $1.02. View the best growth stocks for 2023 here. Are investors shorting Virios Therapeutics? Virios Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 465,100 shares, a decline of 17.9% from the August 15th total of 566,300 shares. Based on an average trading volume of 688,600 shares, the days-to-cover ratio is presently 0.7 days. View Virios Therapeutics' Short Interest. When is Virios Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our VIRI earnings forecast. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its earnings results on Thursday, August, 10th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. When did Virios Therapeutics IPO? (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. What is Virios Therapeutics' stock symbol? Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI." Who are Virios Therapeutics' major shareholders? Virios Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.80%), State Street Corp (0.29%), Citadel Advisors LLC (0.18%), McCollum Christoferson Group LLC (0.17%), Belvedere Trading LLC (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen. View institutional ownership trends. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Virios Therapeutics' stock price today? One share of VIRI stock can currently be purchased for approximately $1.02. How much money does Virios Therapeutics make? Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $19.63 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. How can I contact Virios Therapeutics? The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com. This page (NASDAQ:VIRI) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.